NIFTY  9,612.10  0.18%
  SENSEX  31,088.80  0.20%
 CURRENCY  Rs  64.45/$ 72.07/€, 82.52/£
  GOLD  28,865.00  -0.08%
  SILVER  40,166.00  0.19%
  DAX  12,602.20  -0.15%
  FTSE  7,547.63  0.40%
  CAC  5,336.64  -0.01%
  HANG SENG  25,701.60  0.24%
  NIKKEI  19,682.60  -0.02%
  Shanghai Composite  3,110.06  0.04%
  DOW JONES  21,080.30  -0.01%
  NASDAQ  6,210.19  0.08%
  S&P 500  2,415.82  0.03%
EARNINGS REPORT - Jindal Saw Q4 Total Income At Rs 1,876 Cr Vs Rs 1,902 Cr,Down 1.3% YoY EARNINGS REPORT - IL&FS Invst Managers Q4 Total Revenue Rs 11.4 Cr Vs Rs 37 Cr, Down 69% YoY

Another USFDA Alert For Ranbaxy

Video:

Play this video

September 24: Ranbaxy is in the spotlight again with global regulators starting to show concern. Reports suggest that the European and Australian regulators have sought information from the US FDA on company practices. Meanwhile, USFDA is looking into practices being followed at the Ohm facility in US, which is the only facility of Ranbaxy catering to the entire market now. We also trace the stock since the Daiichi Sankyo acquisition to where it stands right now.